Abdera Therapeutics Inc.’s approach for breaking into what it estimates is a $30bn market for radiopharmaceuticals centers around developing antibodies specifically designed to carry radioisotopes to a tumor, by which it hopes to avoid some of the pitfalls that previous efforts have fallen into.
Abdera Comes Out Of Stealth With Radiopharmaceutical-Specialized Antibody Approach
The company has sought to develop antibodies purpose-built for delivering radiotherapy rather than repurposing existing antibodies for that purpose, as some other players have done.
